GLP-1 Receptor Agonists: A Complete Primer

The short version

GLP-1 receptor agonists (GLP-1 RAs) are a class of injectable and oral drugs that mimic the action of glucagon-like peptide-1, a gut hormone released after eating. They lower blood glucose, suppress appetite, slow gastric emptying, and in large trials have been shown to reduce major cardiovascular events. The class has grown from twice-daily injections with modest weight loss to once-weekly injections with 15 to 20 percent mean body weight reduction and proven cardiovascular benefit even in people without diabetes.

What GLP-1 is

GLP-1 is a 30-amino acid peptide hormone produced by L-cells in the distal small intestine and colon. L-cells release GLP-1 in response to nutrient contact with the gut lumen, particularly fats and carbohydrates. GLP-1 is one of two main incretin hormones (the other is GIP, glucose-dependent insulinotropic polypeptide); together they account for the incretin effect, the observation that oral glucose produces a substantially larger insulin response than the same amount of glucose given intravenously.^[1]

In its native form, GLP-1 has a plasma half-life of approximately 1.5 to 2 minutes. The enzyme DPP-4 (dipeptidyl peptidase-4) cleaves the N-terminal dipeptide, inactivating the hormone almost immediately after secretion.^[2] This is why GLP-1 itself cannot be given as a drug: it would be destroyed before reaching its target organs in any useful quantity. All GLP-1 receptor agonists are structurally modified versions of GLP-1 or related peptides, engineered to resist DPP-4 and survive in circulation long enough to be pharmacologically useful.

The GLP-1 receptor and its locations

The GLP-1 receptor (GLP-1R) is a class B G-protein coupled receptor that signals primarily through adenylyl cyclase (raising intracellular cAMP) and downstream protein kinase A.^[1] It is expressed in several tissues that are relevant to the drug class's effects:

• Pancreatic beta cells: GLP-1R activation stimulates insulin secretion in a glucose-dependent manner, meaning it only works when glucose is elevated. This glucose-dependence is the basis for the low hypoglycemia risk of GLP-1 RAs compared to insulin or sulfonylureas.
• Pancreatic alpha cells: GLP-1R activation suppresses glucagon secretion, reducing hepatic glucose output.
• Stomach: GLP-1R activation slows gastric emptying, blunting postprandial glucose excursions and contributing to early satiety.
• Hypothalamus and hindbrain: GLP-1R in the arcuate nucleus and area postrema (brainstem) reduces food intake centrally by modulating appetite and satiety signaling circuits.
• Heart and vasculature: GLP-1R is expressed on cardiomyocytes and endothelial cells; the mechanisms underlying the cardiovascular benefit observed in outcomes trials are still being characterized and likely include both indirect effects (weight and glucose reduction) and direct cardiac and anti-inflammatory effects.^[1]

Approved GLP-1 receptor agonists: key differences

The class has evolved substantially since exenatide was first approved in 2005. Key members and their distinguishing features:

The structural differences between exendin-4-based drugs (exenatide, lixisenatide) and human GLP-1-based drugs (liraglutide, semaglutide, dulaglutide) have some clinical consequences. Exendin-4-based drugs have a higher rate of antibody formation, which in some patients may reduce efficacy over time. Human GLP-1-based drugs have lower immunogenicity. Semaglutide's oral formulation (Rybelsus) uses an absorption enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to allow the peptide to be absorbed across the gastric mucosa rather than degraded in the gut.^[7]

Pivotal cardiovascular outcomes trials

A 2008 FDA guidance for T2DM drugs required that new drugs demonstrate cardiovascular safety through large outcomes trials. Several GLP-1 RA trials went further and showed cardiovascular benefit:

LEADER (liraglutide, 2016)

9,340 participants with T2DM and high cardiovascular risk; median follow-up 3.8 years. Liraglutide reduced the primary composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% versus placebo (HR 0.87, 95% CI 0.78-0.97, p=0.01 for superiority).^[3] Cardiovascular death was the main driver. The LEADER trial established liraglutide as the first GLP-1 RA with proven cardiovascular benefit.

SUSTAIN-6 (semaglutide injectable, 2016)

3,297 participants with T2DM; primarily a cardiovascular safety trial. Semaglutide reduced MACE by 26% (HR 0.74, 95% CI 0.58-0.95, p=0.02 for noninferiority and p=0.02 for superiority).^[4] Nonfatal stroke was the most prominent component driving the effect. SUSTAIN-6 was underpowered for superiority as a pre-specified objective; the SELECT trial later provided larger confirmatory evidence.

SELECT (semaglutide, obesity without diabetes, 2023)

17,604 participants with obesity (BMI 27 or higher) and established cardiovascular disease but no diabetes at baseline. Semaglutide 2.4 mg weekly reduced MACE by 20% (HR 0.80, 95% CI 0.72-0.90, p<0.001).^[5] SELECT is notable because it established cardiovascular benefit specifically in people without diabetes, expanding the indication and the pharmacological understanding of how GLP-1 RAs reduce risk beyond glucose control alone.

Dual and triple agonists

The GLP-1 receptor agonist concept has been extended to molecules that activate multiple incretin or metabolic receptors simultaneously.

Tirzepatide (Mounjaro / Zepbound) is a dual GLP-1 and GIP receptor agonist approved for T2DM (2022) and chronic weight management (2023). In SURMOUNT-1, participants with obesity treated with tirzepatide 15 mg weekly achieved a mean 22.5% reduction in body weight at 72 weeks versus 2.4% with placebo.^[6]Head-to-head data from SURPASS-2 showed superior HbA1c and weight reduction versus semaglutide 1 mg in T2DM. Whether the incremental benefit over a weight-matched high-dose GLP-1 RA reflects GIP receptor agonism or dose is an open mechanistic question.

Triagonists targeting GLP-1, GIP, and glucagon receptors simultaneously are in clinical development. Glucagon receptor agonism increases energy expenditure and promotes hepatic fat oxidation; combining this with the appetite-suppressing effects of GLP-1R and the metabolic effects of GIPR agonism is the pharmacological rationale. Early-phase data suggest that triagonists may achieve even larger weight reductions, but large safety and outcomes trials have not yet been completed as of 2026.^[9]

Class boxed warning: thyroid C-cell tumors

All approved GLP-1 receptor agonists carry an FDA boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC).^[8] This warning is based on findings in rodent studies where GLP-1R agonism at high doses over prolonged periods caused dose-dependent C-cell hyperplasia and tumors. Rodent thyroid C-cells express GLP-1 receptors at much higher density than human C-cells, and the relevance of these animal findings to humans is uncertain. Epidemiological data and the large clinical trials have not demonstrated a statistically significant increase in MTC risk, but the trials were not designed or powered to detect this rare outcome, and post-marketing surveillance continues.

Based on this warning, GLP-1 receptor agonists are contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN-2)

Gastrointestinal side effect profile

Gastrointestinal adverse events are the most common side effects of GLP-1 receptor agonists and are the primary reason for discontinuation. They are mechanistically linked to the drug's intended effects: slowed gastric emptying causes nausea, early satiety, and vomiting; GLP-1R activation in the gut and central nervous system contributes to nausea and sometimes diarrhea.^[7]

Typical incidence rates from pivotal trials:

• Nausea: 15 to 44% (drug and dose dependent), most common during dose escalation
• Vomiting: 5 to 24%
• Diarrhea: 8 to 30%
• Constipation: 5 to 24% (particularly with tirzepatide)

Most GI side effects are transient and peak during dose escalation. Gradual dose escalation protocols (for example, starting semaglutide at 0.25 mg/week for 4 weeks before increasing) substantially reduce the proportion of patients who discontinue due to GI events. Patients who take the drug with food and avoid lying down immediately after eating also tend to tolerate it better.

Less common but important adverse events include pancreatitis (rare, mechanism unclear, monitoring warranted if symptoms occur), gallbladder disease including cholelithiasis (weight loss accelerates stone formation), and for patients with pre-existing gastroparesis, worsening of gastric motility.

Where the science is going

Several directions are active in GLP-1 RA research as of 2026:

• Triagonists (GLP-1 / GIP / glucagon): retatrutide and other molecules adding glucagon receptor agonism to the dual incretin framework. Early data suggest 24% or greater mean weight loss in phase 2 trials. Phase 3 programs are underway but no large cardiovascular outcomes data are available yet.^[9]
• Oral peptides: semaglutide tablets (Rybelsus) are the first oral GLP-1 RA. The absorption challenge (protecting a peptide from gastric acid and proteases, then achieving meaningful intestinal uptake) is formidable. Other approaches including microneedle patches, ionic liquid formulations, and nanoparticle delivery are in development. Oral administration would expand access to patients who cannot or will not self-inject.
• Combination with amylin analogs: cagrilintide, an amylin analog, combined with semaglutide (as cagrisema) has shown additive weight loss in early trials. Amylin works partly through different central satiety circuits from GLP-1, suggesting complementary mechanisms.
• Non-alcoholic steatohepatitis (MASH): semaglutide has shown histological improvement in MASH in phase 2; larger phase 3 trials are examining whether this translates to reduced fibrosis and liver-related outcomes.
• Cognitive and neurodegenerative outcomes: observational data and small trials suggest possible protective effects of GLP-1 RAs on Alzheimer's disease and Parkinson's disease. This is hypothesis-generating; large prospective trials are needed.